title: Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.
authors.affiliation: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
authors.forename: M S
authors.initials: MS
authors.lastname: Zabriskie
authors.affiliation: Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.|Howard Hughes Medical Institute, Portland, OR, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Eide
authors.affiliation: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
authors.forename: D
authors.initials: D
authors.lastname: Yan
authors.affiliation: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
authors.forename: N A
authors.initials: NA
authors.lastname: Vellore
authors.affiliation: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
authors.forename: A D
authors.initials: AD
authors.lastname: Pomicter
authors.affiliation: Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
authors.forename: S L
authors.initials: SL
authors.lastname: Savage
authors.affiliation: Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.|Howard Hughes Medical Institute, Portland, OR, USA.
authors.forename: B J
authors.initials: BJ
authors.lastname: Druker
authors.affiliation: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.|Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA.
authors.forename: M W
authors.initials: MW
authors.lastname: Deininger
authors.affiliation: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.|Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA.
authors.forename: T
authors.initials: T
authors.lastname: O'Hare
mesh_terms: D000077784:Axitinib; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007191:Indazoles / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D009154:Mutation / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D000077784:Axitinib; D016044:Fusion Proteins, bcr-abl